Publication: 4626

Publication: 4626

Naloxegol, an Oral Peripherally Acting Opioid Receptor Antagonist, Administered Concurrently with First-Line Systemic Therapy for Advanced Lung Adenocarcinoma (Alliance A221504): A Feasibility and Safety Study

PubMed

PMC

QxMD

DOI

Google Scholar

Citation:: Cancers (Basel) vol 18 (3)

Year:: 2026
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: epub-ppub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:: 15

Parents:: None
Children:: None

Program:: CCP
Primary Committee:: Symptom Inter
Sec. Committees:: Respiratory

Pharmas:: AstraZeneca
Grants:: UG1CA189823, UG1CA233327; U10CA180888 (SWOG)

Corr. Author:
Authors:: Pankaj Gupta Kalpna Gupta Travis Dockter Elizabeth Harlos Selina Chow Niveditha Subbiah Kathryn J. Ruddy Lyudmila Bazhenova Shelby Terstriep Chao H. Huang Robert A. Kratzke Everett E. Vokes Charles L. Loprinzi

Networks:: CA249, KANSAS, LAPS-IL057, LAPS-MN026, MN022, SANFORD

Study: Alliance-A221504
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 3

Keywords: